<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03491358</url>
  </required_header>
  <id_info>
    <org_study_id>SOLO ALLERGEN 18</org_study_id>
    <nct_id>NCT03491358</nct_id>
  </id_info>
  <brief_title>Inhaled Allergen Challenge Methodology: Assessment of a Vibrating Mesh Nebulizer for Allergen Administration</brief_title>
  <official_title>Inhaled Allergen Challenge Methodology: Assessment of a Vibrating Mesh Nebulizer for Allergen Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the Aerogen Solo® (Solo®) vibrating mesh nebulizer as a potential new
      device for use in allergen challenge testing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center, randomized, cross-over study utilizing the expertise of three
      Canadian academic centers (University of Saskatchewan, McMaster University, Laval University)
      that have been performing allergen inhalation challenges and other bronchoprovocation studies
      for more than forty years.

      Each participant will be required to attend the research lab on five occasions (Visits 1-5).
      At Visit 1, study staff will provide an overview of the study purpose and procedure and
      answer any questions the participant may have. The individual will then provide consent if
      they wish to participate (i.e. sign the consent form). Skin prick testing to determine
      relevant allergen sensitivities and to determine which allergen extract will be used for the
      skin test endpoint (STE) and allergen inhalation challenge will then be performed. The
      participant will be randomized with respect to which nebulizer (Solo® or Wright) will be used
      first. The choice of nebulizer for the first participant will be via blinded draw. Subsequent
      nebulizer assignments will alternate. Participants will undergo the STE procedure and
      methacholine challenge testing (MCT) at visit 2; an allergen challenge will be done the next
      day at Visit 3 using the same nebulizer as was used for the MCT at Visit 2. Visits 4 and 5
      will also be performed on consecutive days and will involve methacholine and allergen
      challenge testing, respectively, using the nebulizer that was not used at Visits 2 and 3. A
      minimum of two weeks must separate Visits 3 and 4.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Allergen Solo EAR PD20 (provocative dose causing a 20% fall in forced expiratory volume, FEV1)</measure>
    <time_frame>Baseline</time_frame>
    <description>Record the dose of allergen required to induce a 20% fall in forced expiratory volume using the Solo device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predicted allergen Solo EAR PD20</measure>
    <time_frame>Baseline (based on baseline methacholine challenge and skin test endpoint results)</time_frame>
    <description>Will be predicted using the standard equation that employs the STE and MCT results</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Wright jet nebulizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will employ the Wright jet nebulizer for use in an allergen challenge triad</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solo vibrating mesh nebulizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will employ the Aerogen Solo vibrating mesh device for use in an allergen challenge triad</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wright jet nebulizer</intervention_name>
    <description>Roxon Medi-Tech, Montreal, QC, Canada</description>
    <arm_group_label>Wright jet nebulizer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aerogen Solo</intervention_name>
    <description>Aerogen Ltd., Galway, Ireland</description>
    <arm_group_label>Solo vibrating mesh nebulizer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  baseline FEV1 greater than or equal to 70%

          -  positive response to inhaled methacholine (i.e. PD20 less than 400mcg)

          -  evidence of atopy (i.e. positive skin prick test to an allergen that can be used for
             the inhalation challenge

          -  absence of respiratory infection for at least 4 weeks

          -  absence of allergen exposure (or other trigger of upper or lower respiratory symptoms)
             for at least 4 weeks

          -  current nonsmoker (ex-smoker allowed; case by case basis; investigator discretion)

          -  require only infrequent short-acting beta2 agonist (i.e. salbutamol or terbutaline) to
             treat/control asthma (i.e. no inhaled corticosteroid or combination therapies, no
             intranasal corticosteroid; anti-histamines etc.)

          -  general good health with no other medical condition, medication use or lifestyle
             activities that would influence the outcome of the allergen challenge

        Exclusion Criteria:

          -  pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Don Cockcroft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Don Cockcroft, MD</last_name>
    <phone>306-844-1446</phone>
    <email>don.cockcroft@usask.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Gail Gauvreau, PhD</last_name>
      <email>gauvreau@mcmaster.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laval University</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Eve Boulay, MSc</last_name>
      <email>marie-eve.boulay@criucpq.ulaval.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asthma Research Lab - University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Don Cockcroft, MD</last_name>
      <phone>306-844-1446</phone>
      <email>don.cockcroft@usask.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Beth Davis, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2018</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Don Cockcroft</investigator_full_name>
    <investigator_title>Professor, College of Medicine</investigator_title>
  </responsible_party>
  <keyword>vibrating mesh nebulizer</keyword>
  <keyword>allergen challenge</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

